Company Research Report: Torigen Pharmaceuticals, Inc.

Company Overview

Name and Mission of the Company

Name: Torigen Pharmaceuticals, Inc.

Mission: Torigen Pharmaceuticals is dedicated to providing advanced cancer care solutions for companion animals, driven by a passion and love for pets to extend their lives despite cancer diagnoses.

Founding and Founders

Founded by: Ashley Kalinauskas, based on her graduate thesis project.

Key People in the Company

Ashley Kalinauskas: Chief Executive Officer

Dr. Mark Suckow: Chief Technology Officer

Dr. Michael Lucroy: Chief Medical Officer

Dr. Ryan Clauson: VP of Research and Development

Sean Fitzgerald: VP of Market Development

Headquarters

Location: 6 Executive Dr., Suite 118, Farmington, CT 06032

Number of Employees

No information is available

Revenue

No information is available

Company Recognition

Known For: Producing experimental autologous cancer vaccines for companion animals. The company's technology harnesses the immune system to fight cancer in pets.

Products

Experimental Autologous Cancer Vaccine

High-Level Description: This product is an experimental autologous prescription product regulated by the USDA Center for Veterinary Biologics, designed for use under the supervision or prescription of a licensed veterinarian.

Key Features:

Personalized cancer treatment for companion animals.

Created utilizing a unique MIM-SIS adjuvant.

Applicable for any type of solid tumor in pets.

Recent Developments

New Partnerships and Collaborations

Preferred Partner Agreement with Veterinary Management Groups: Announced on April 13, 2023.

National Distribution Deal with MWI Animal Health: Announced on July 5, 2022.

Strategic Partnership with Vidium Animal Health to expand histopathology services: Announced on April 27, 2022.

Distribution Agreements with Victor Medical Group: Signed June 11, 2021.

New Headquarters and Leadership Promotions

Headquarters: Torigen Pharmaceuticals opened a new headquarters as announced on April 25, 2023.

Executive Leadership Promotions: Promoted two individuals to executive leadership positions.

Financial Growth

$13 Million Capital Raise: Announced completion on November 17, 2022.

Product Development

The company is progressing in the field of autologous cancer vaccine (ACV) technology, focusing on advancements in immunotherapy for companion animals.

Publications and Media Presence

Scientific Publications: Numerous studies and articles published in reputable journals focusing on the safety and efficacy of autologous cancer vaccines for various animals.

Media Features: Torigen has been featured in various podcasts and interviews, discussing advances in veterinary oncology and their unique approaches to cancer treatment for pets.

Expansion and Innovation

Torigen Pharmaceuticals is actively working on expanding its technology pipeline and is interested in business development opportunities and international expansion as of the latest announcements.

Conclusion

This report provides an extensive overview of Torigen Pharmaceuticals, Inc., highlighting significant aspects of their mission, key personnel, products, and recent developments. The company stands at the forefront of veterinary oncology with its innovative approaches to cancer immunotherapy for companion animals.